Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Maxcyte Inc (MXCT)

Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Mar 31, 3:05PM CDT

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance GlobeNewswire - Tue Mar 24, 3:05PM CDT

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer GlobeNewswire - Mon Mar 23, 7:05AM CDT

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery GlobeNewswire - Tue Feb 24, 7:05AM CST

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 GlobeNewswire - Mon Feb 23, 3:05PM CST

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Mon Jan 12, 7:05AM CST

ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Announces Planned CFO Transition in 2026 GlobeNewswire - Wed Nov 12, 2025

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance GlobeNewswire - Wed Nov 12, 2025

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 GlobeNewswire - Wed Oct 8, 2025

ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors GlobeNewswire - Mon Oct 6, 2025

ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and...

MXCN.LN : 680.000 (unch)
MXCT.LN : 152.000 (-5.00%)
MXCT : 0.7441 (+5.92%)

Barchart Exclusives

This Dividend Stock Has Been Steady Amid the Iran War: Is It Still a Buy? Barchart - Wed Apr 1, 6:30PM CDT
Citigroup has a dividend yield of over 2.2% and has outperformed the markets over the last month. Is the stock still a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.